Filing Details
- Accession Number:
- 0001104659-23-082736
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-20 16:20:03
- Reporting Period:
- 2023-07-18
- Accepted Time:
- 2023-07-20 16:20:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1400118 | Sagimet Biosciences Inc. | SGMT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1184592 | C Beth Seidenberg | Sagimet Biosciences Inc. 155 Bovet Road, Suite 303 San Mateo CA 94402 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-07-18 | 38,763 | $0.00 | 0 | No | 4 | D | Indirect | See footnote |
| Series A Common Stock | Acquisiton | 2023-07-18 | 38,763 | $0.00 | 38,763 | No | 4 | A | Indirect | See footnote |
| Series A Common Stock | Acquisiton | 2023-07-18 | 1,860,712 | $0.00 | 1,899,475 | No | 4 | C | Indirect | See footnote |
| Series A Common Stock | Acquisiton | 2023-07-18 | 84,768 | $0.00 | 84,768 | No | 4 | C | Direct | |
| Series A Common Stock | Acquisiton | 2023-07-18 | 46,875 | $16.00 | 46,875 | No | 4 | P | Indirect | By trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | D | Indirect | See footnote |
| No | 4 | A | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Direct | |
| No | 4 | P | Indirect | By trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Series A Common Stock | Series A Preferred Stock | Disposition | 2023-07-18 | 539,006 | $0.00 | 6,781 | $0.00 |
| Series A Common Stock | Series B Preferred Stock | Disposition | 2023-07-18 | 493,370 | $0.00 | 6,208 | $0.00 |
| Series A Common Stock | Series B-1 Preferred Stock | Disposition | 2023-07-18 | 8,596,590 | $0.00 | 108,163 | $0.00 |
| Series A Common Stock | Series C Preferred Stock | Disposition | 2023-07-18 | 8,596,589 | $0.00 | 108,163 | $0.00 |
| Series A Common Stock | Series D Preferred Stock | Disposition | 2023-07-18 | 6,103,580 | $0.00 | 76,796 | $0.00 |
| Series A Common Stock | Series E Preferred Stock | Disposition | 2023-07-18 | 6,737,254 | $0.00 | 84,768 | $0.00 |
| Series A Common Stock | Series E Preferred Stock | Disposition | 2023-07-18 | 103,127,234 | $0.00 | 1,297,549 | $0.00 |
| Series A Common Stock | Series F Preferred Stock | Disposition | 2023-07-18 | 20,430,107 | $0.00 | 257,052 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-07-18 | 23,216 | $0.00 | 23,216 | $6.36 |
| Series A Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-07-18 | 23,216 | $0.00 | 23,216 | $6.36 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | 2029-04-28 | No | 4 | D | Direct | |
| 23,216 | 2029-04-28 | No | 4 | A | Direct |
Footnotes
- Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
- Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date.
- Shares held directly by the Reporting Person. Such shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee".
- Shares held by the Seidenberg/Vogel Revocable Trust UA 3/6/03, of which the Reporting Person serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
- The shares underlying this option are fully vested and exercisable as of the date hereof.
Billionaire Hedge Funds
